PSYCH NEWS – 18/02/26
In February 2026, major advances in psychedelic medicine included a rapid 25-minute DMT therapy showing strong results for depression, psilocybin moving closer to regulatory approval, growing evidence that ketamine’s benefits may not depend on the “trip”, expanded FDA … The post PSYCH NEWS – 18/02/26 appeared first on Chemical Collective.
External link. We are not responsible for the content.
Read more ↗More From Chemical Collective
Psychedelics and Compassion Overload
Psychedelic experiences can enhance empathy and compassion in ways that support mental health and therapeutic outcome...
Comment perfectionner la préparation de son trip ?
La préparation d’un voyage est un processus à la fois intérieur et extérieur – qui consiste à aligner l’intention, l’...
Psychedelics and Somatic Flashbacks
Somatic flashbacks involve the re-experiencing of intense bodily sensations from a traumatic event. While psychedelic...
Latest News
Here’s Why Some Ayahuasca Journeys Hit Harder Than Others
PLUS, how to get your parents interested in mushrooms, eco anxiety, and Gonzo lore. [...] Read More... The post Here’...
Authors of Largest Microdosing Study Suggest Benefits Limited To Dosing Day
Recent research surveying 1,435 microdosers suggests that microdosing’s duration of effect might be more like that of...
The FDA is changing the drug approval process; In a Senate hearing, Surgeon General nominee Casey Means was asked about psychedelics use
Plus: RAND survey shows that nearly a quarter of U.S. adults support legal use of psilocybin mushrooms; Reunion Neuro...
Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials
In this conversation with Psychedelic Alpha’s Josh Hardman, Dr. Terence Ching discusses his journey into the field an...
Can Psychedelics Break the Consumption Cycle?
Consumer culture doesn’t just shape what we buy — it shapes what we want. Here’s why that’s harder to escape than you...